Continuous Glucose Monitoring Glycemic cHAracterization During Pregnancy

Launched by KK WOMEN'S AND CHILDREN'S HOSPITAL · Apr 5, 2024

Keywords

ClinConnect Summary

This clinical trial, called the Integrated Continuous Glucose Monitoring (CGM) Glycemic Characterization During Pregnancy (I-CHAP), is studying how effective continuous glucose monitoring is for diagnosing gestational diabetes in pregnant women. The researchers want to see if the data from CGM can provide useful information compared to the traditional oral glucose tolerance test (OGTT). They aim to find out if the glucose readings from the CGM during fasting and after drinking a sugary solution match up with the results from the OGTT, how these readings relate to the health of both the mother and baby, and whether women find using the CGM more comfortable than the OGTT.

To participate in this study, women need to be between 21 and 45 years old, of Chinese or Indian ethnicity, and scheduled for an OGTT between 20 and 35 weeks of pregnancy at KK Women's and Children's Hospital. Women with certain skin conditions or pre-existing diabetes, as well as those who were diagnosed with gestational diabetes early in their pregnancy, cannot join. Participants will wear a CGM device for 10 days, which continuously tracks glucose levels, and will also undergo the traditional OGTT to compare the results. This study is currently recruiting participants, and it’s an important step in understanding how to better diagnose and manage gestational diabetes in pregnant women.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Pregnant women of only Chinese or Indian ethnicity
• • 2. Pregnant women between age 21--45 years old
• • 3. Oral glucose tolerance test (OGTT) to be scheduled between 20-35 weeks gestational age
• • 4. OGTT to be done at KK Women's and Children's Hospital
• Exclusion Criteria:
• • 1. Women with serious skin conditions (e.g. eczema) that precludes wearing the sensor for 10 days
• • 2. Exclusion criteria were pre-existing Type 1 or Type 2 diabetes, mental illness precluding informed consent and women who were diagnosed early (1st or early 2nd trimester for GDM).